Guide on Drugs for Cytomegalovirus in Transplants
Federal Register notice: FDA makes available a final guidance entitled “Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease.” The document is intended to assist sponsors in all phases of the clinical development of drugs and biological products to treat or prevent cytomegalovirus disease in patients who have undergone solid organ transplantation or hematopoietic stem cell transplantation. To view the notice, click here.